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Background: Due to adjuvant treatment concepts for patients with R0-resected
gastrointestinal stromal tumors (GIST), a reproducible and reliable risk classification
system proved of utmost importance for optimal treatment of patients and prediction
of prognosis. The aim of this study was to reevaluate the impact of five widely-applied
and well-established GIST risk classification systems (i.e., scores by Fletcher, Miettinen,
Huang, Joensuu, and TNM classification) on a series of 558 GIST patients with long-term
follow-up after R0 resection.
Methods: Tumor size, mitotic count and site were used in variable combination to
predict high- and low risk patients by the use of the five risk classification models. For
survival analyses disease-specific survival, disease-free survival and overall-survival were
investigated. Patients with initial metastatic disease or incompletely resectable tumors
were excluded.
Results: All GIST classification models distinguished well between patients with
high-risk and low-risk tumors and none of the five risk systems was superior to predict
patient outcome. The models showed significant heterogeneity. There was no significant
difference between the different risk-groups regarding overall-survival. Subdivision of
GIST patients with very low- and low-risk appeared to be negligible.
Conclusions: Currently applied GIST risk classification systems are comparable to
predict high- or low-risk patients with initial non-metastatic and completely resected
GIST. However, the heterogeneity of the high-risk group and the absence of differences
in overall survival indicate the need for more precise tumor- and patient-related criteria
for better stratification of GIST and identification of patients who would benefit best from
adjuvant tyrosine kinase inhibitor therapy.
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INTRODUCTION
Gastrointestinal stromal tumors (GIST) are the most common
mesenchymal neoplasms of the gastrointestinal tract with an
annual incidence of 7–20 per million (Tran et al., 2005; Nilsson
et al., 2005; Tryggvason et al., 2007; Tzen et al., 2007; Steigen
et al., 2008; Cassier et al., 2010), but their incidence might be
underestimated (Choi et al., 2015). There is substantial evidence
that GISTs differentiate similar to the gut pacemaker cells, the
interstitial cells of Cajal (Barajas-López et al., 1989), suggesting
an origin from these or their mesenchymal progenitor cells
(Kitamura et al., 1998; Miettinen et al., 1999). While a majority
of GISTs (∼80%) are driven by gain-of-function mutations in
the proto-oncogene KIT on chromosome 4q11-21 (Hirota et al.,
1998; Kindblom et al., 1998; Sommer et al., 2003; Rubin et al.,
2005), about 20% of GIST lack KIT mutations but either carrying
gain-of-function mutations of the KIT homolog platelet-derived
growth factor receptor alpha (PDGFRA), or wildtype for both
genes. Most GISTs are diagnosed in the 6–7th decade of life
(Miettinen et al., 2005; Woodall et al., 2009).
Complete surgical resection of the tumor is still the gold
standard of treatment of patients with resectable localized
disease. However, the impact of powerful tyrosine kinase
inhibitors (TKI), like imatinib mesylate, as targeted therapy in
GIST is increasing as adjuvant (Dematteo et al., 2009; Joensuu
et al., 2012a) or supportive (palliative) (Blanke et al., 2008a,b)
therapy in patients with high risk and advanced/unresectable
disease. Though proven highly effective as first-line therapy for
metastatic disease, a wide spectrum of TKI-related side effects
and high socio-economic treatment costs (Rubin et al., 2010)
make it necessary to establish better criteria for the decision
making process. In addition to the TKI use as durable first-
line treatment for metastatic GIST, guidelines of the European
Society For Medical Oncology (ESMO) (The ESMO/European
Sarcoma Network Working Group, 2014) and the National
Comprehensive Cancer Network (NCCN) recommend the
adjuvant use of TKI for patients with “a significant risk of relapse,”
particularly those with high risk tumors but also for tumors
with intermediate risk up to 3 years (Joensuu et al., 2012a).
However, a precise definition of a “significant risk of relapse” is
challenging as almost one half of patients in the intermediate-
and high-risk group will not develop metachronous disease
progression. Furthermore, the current ESMO guidelines (The
ESMO/European Sarcoma Network Working Group, 2014)
mainly recommend the use of the criteria of Miettinen and
Lasota (2006), but in common clinical practice risk assessment
depends strongly on the center-specific expertise of the respective
pathologists and/or oncologists. Accordingly, there is a clinical
need for a more reliable risk classification system that is
simple to apply and able to stratify more precisely high-
risk-, low-risk, and very-low-risk patients for progression of
disease.
In the past, more than eight GIST classification systems have
been established. The classification scores by Fletcher et al. (2002)
and Miettinen and Lasota (2006) are most widely clinically
accepted. Nevertheless, independent reevaluation even of these
classification systems in lager cohorts is limited.
In 2002, Fletcher et al. proposed the first risk classification
system for GISTwhich is currently termed as “NIH classification”
by some authors (Fletcher et al., 2002). Based on size (the single
largest dimension) and mitotic count in 50 high power fields
(HPF), a four grade scale to predict biological behavior was
proposed according to the former work of Franquemont et al.
(Franquemont and Frierson, 1992). Subsequently, GISTs were
divided into four groups with high, intermediate, low and very
low risk of progression, thereby excluding a benign category. The
usefulness of this classification has been proved in several studies
(Nilsson et al., 2005; Andersson et al., 2006; Mucciarini et al.,
2007; Rutkowski et al., 2007; Takahashi et al., 2007; Goh et al.,
2008; Hassan et al., 2008; Joensuu et al., 2012b). Nevertheless, the
area of 50 HPFs is imprecisely defined.
In 2006, Miettinen et al. published a new classification based
on the evaluation of 1765 GIST of the stomach and 906 GIST of
the small intestine (Miettinen et al., 2005, 2006; Miettinen and
Lasota, 2006) which is also termed as the Armed Forces Institute
of Pathology (AFIP) classification. The main criteria were also
mitotic count and primary tumor size. However, based on the
observation that gastric GISTs showed a much lower rate of
aggressive behavior than comparable intestinal GISTs, Miettinen
et al. introduced the anatomic site of the primary tumor as an
additional criterion in risk assessment. They were also the first to
specify the total area for mitotic counting (5 mm2). Using these
three parameters, eight subgroups (group 1–6b) corresponding to
five risk groups were established. In contrast to Fletcher et al. the
Miettinen et al. classification considers a no risk/benign group.
The main differences to the NIH-classification are a general
downgrading of gastric tumors and an upgrading of a subset of
non-gastric tumors. Therefore, in this classification, localization
as a risk factor is more articulately appreciated.
In 2007, Huang et al. reevaluated NIH consensus criteria
according to Fletcher et al. (2002), in n= 289 cases (Huang et al.,
2007). They found no significant differences between the very low
and low risk group, thereby merging both as “Level I” risk group.
Due to a prognostic heterogeneity in the high-risk category of
the NIH scheme, only GIST with a size >5 cm and >10 mitoses
per 50 HPFs were rated as Level IV. The total area for mitotic
counting was defined as 11.85 mm2.
Based on these new findings, Goh et al. proposed a revision of
the AFIP-criteria (Goh et al., 2008) in 2008. They also merged
very-low and low-risk patients to one group and introduced a
very-high risk group, which corresponds to the high-risk group
defined by Huang et al. (2007).
In 2008, Joensuu et al. published a large review on prognostic
factors in GIST (Joensuu, 2008). Based on data by Takahashi
et al. (2007) and Rutkowski et al. (2007), who found a negative
prognostic effect of tumor rupture during surgery, he proposed
a new risk classification and defined tumor rupture as an
important prognostic parameter for high risk. The “modified
NIH classification” was based on the classification presented
by Fletcher et al. and Miettinen et al. The major differences
to the original NIH system were the definition of tumors with
exactly 5 cm diameter or 5 mitoses/50 HPFs, the consideration
of tumor rupture as well as tumor site. However, the revised
NIH classification by Joensuu neglected again the area of HPF.
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Later, Joensuu et al. published a comparative analysis of a pooled
population-based cohort including 2560 patients from several
trials (Nilsson et al., 2005; Mucciarini et al., 2007; Rutkowski
et al., 2007; Steigen et al., 2007; Takahashi et al., 2007; Tryggvason
et al., 2007; Braconi et al., 2008; Mazzola et al., 2008; Brabec et al.,
2009) with a median follow-up time for patients alive of 4.0 years
(Joensuu et al., 2012b). They investigated the predictive value of
the NIH consensus criteria (Fletcher et al., 2002), the modified
consensus criteria according to Joensuu (2008) and the AFIP
criteria according to Miettinen and Lasota (2006). The authors
concluded that the previously presented criteria identified high-
risk patients at best which has been confirmed by other groups
(Jang et al., 2014; Yanagimoto et al., 2015).
In 2010 the first TNM classification for GIST was published
(Sobin et al., 2010). This system actually adopted the classification
of Miettinen et al., including the definition of mitotic area which
was defined as 5 mm2. However, the TNM classification has
mainly focused on renaming the eight subgroups defined by
Miettinen et al. to represent various tumor stages. A minor
modification considered metastasis as a stage IV disease similar
to other cancer types. The high-risk group introduced by
Miettinen and Lasota (2006) corresponds to stage III. The ESMO
guidelines do not recommend the use of this classification in its
current form (The ESMO/European Sarcoma Network Working
Group, 2014). Recently, Agaimy proposed an “integrated risk
system” (Agaimy, 2013) by integration of the criteria ofMiettinen
et al., Joensuu as well as a “clinically malignant” category.
Finally, several authors have presented nomograms and heat
maps for predicting the outcome where mostly tumor size,
mitotic index and localization of the primary tumor are used
either as continuous or as discrete variables (Gold et al., 2009;
Rossi et al., 2011; Bischof et al., 2014).
Table 1 gives an overview of the different classification
systems.
Meanwhile, several authors, as well as the current ESMO
guidelines, have recommended the standardization of mitotic
counting for GIST. The ESMO suggests a total area of 5 mm2
for counting mitotic figures based on retrospective analyses using
AFIP microscopes, an approach which was not validated by
independent studies. Depending on the field-of-view number
(FOV) and the applied eyepiece, the field area per HPF (e.g.,
∼0.26 mm2 with FOV 23, ∼0.33 mm2 with FOV 26)—and
therefore the necessary number of HPF to count—differs from
microscope to microscope. Ignoring this, mitotic rate might be
consequently overestimated up to 3.1-fold (e.g., counting 50
instead of 16 HPFs) resulting in upgrading of patients’ risk—at
least in a number of cases.
With respect of the emerging initiative of standardization of
established risk classification systems for GIST and standardized
mitotic counting (Agaimy, 2010; Patel, 2011), the aim of this
study was to re-evaluate the predictive value of relevant risk
assessment tools for GIST in a series of 558 patients.
MATERIALS AND METHODS
This study included patients with histologically confirmed
diagnosis of GIST from themulti-center Ulmer GIST Registry—a
multi-center network encompassing 18 oncological centers
in South Germany—from 2006 to 2012. The patients were
registered according to the User’s Guide to Registries Evaluating
Patient Outcomes and to the Strengthening (of) the Reporting
of Observational Studies in Epidemiology (STROBE) Statement
(Vandenbroucke et al., 2007a,b,c; Gliklich and Dreyer, 2010;
Kramer, 2012). All cooperating centers are non-restricted,
open hospitals implicating neither demographic nor social or
clinical selection bias. Patients diagnosed before 2006 were
registered retrospectively. Since 2006, registration and follow
up were intended to be prospectively. After obtaining patients’
consent, descriptive and clinical data were collected frommedical
records by a personal patient contact and/or contact with
the treating physicians. The Ulmer GIST registry has been
previously described in detail (Lott et al., 2015; Kramer et al.,
2015a,b). Only patients with initial non-metastatic R0-resected
gastric and small bowel GISTs were included in this analysis.
Consequently, patients with primary metastatic disease and those
with incomplete resectable tumors were excluded.
The following GIST risk classification models were applied in
this study: Fletcher et al. (2002), Miettinen and Lasota (2006),
Huang et al. (2007), Joensuu (2008), and the TNM-system (Sobin
et al., 2010). Mitotic count areas have been considered so far
as given: Miettinen and Lasota (2006) (5 mm2), Huang et al.
(2007) (11.85 mm2), and the TNM classification (Sobin et al.,
2010) (5 mm2). In accordance with the recommendation by
Miettinen et al. to limit mitotic counting to 25 HPFs in wide-
field-microscopes, a calculated area of 7.5 mm2 was used to re-
evaluate the classification system of Fletcher et al. (2002) and
Joensuu (2008) (revised NIH criteria).
Area-standardized mitotic rates were gained by calculation,
only if a mitotic rate in 50 HPFs and at least 15 mm2
was provided. After calculation of the total counted area A
using the field-of-view number f (diameter of the view field
in millimeters measured at the intermediate image plane) and
the magnification of the objective m0 = 40 in the formula
A =
((
f
2×m0
)2
×pi
)
mm2, the absolute value of the mitotic rate
was interpolated to 5 mm2 for the classifications according to
Miettinen and Lasota (2006) and TNM (Sobin et al., 2010), to
7.5 mm2 for the classifications according to Fletcher et al. (2002)
and Joensuu (2008), as well as to 11.85 mm2 for the classification
according to Huang et al. (2007). Tumors were assigned to the
respective risk group afterwards.
Throughout the manuscript we used an adapted uniform
nomenclature. Most of the classification systems propose a four-
point scale: high risk group, intermediate, low and very low
risk group. With regard to the TNM classification, stage III was
assigned to high-risk patients. For calculation of the predictive
value of the highest risk category all other GIST risk groups
(i.e., intermediate-, low-, and very low-risk group) were merged,
collectively termed as “non-high risk group.”
The classification system by Woodall et al. (2009) could not
be considered due to the lack of data on tumor grading. The
nomograms by Gold et al. (2009), Rossi et al. (2011), and Bischof
et al. (2014) resulting in continuous values were not considered
in our study because all other classifications tools provide ordinal
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TABLE 1 | Overview of different risk classification systems for GIST considering different sites, tumor size and mitotic rates using uniform nomenclature.
Gaster Small intestine
Size Mitotic rate Fletcher Miettinen Huang Joensuu TNM T TNM S Fletcher Miettinen Huang Joensuu TNM T TNM S
≤2 cm ≤5 I 0 I I T1 IA I 0 I I T1 I
>5 and ≤10 III 0 II III T1 II III IV II III T1 IIIA
>10 IV 0 III IV T1 II IV IV III IV T1 IIIA
>2 and
≤5 cm
≤5 II I I II T2 IA II II I II T2 I
>5 and ≤10 III III II III T2 II III IV II III T2 IIIB
>10 IV III III III T2 II IV IV III IV T2 IIIB
>5 and
≤10 cm
≤5 III II II III T3 IB III III II IV T3 II
>5 and ≤10 IV IV III IV T3 IIIA IV IV III IV T3 IIIB
>10 IV IV IV IV T3 IIIA IV IV IV IV T3 IIIB
>10 cm ≤5 IV III IV IV T4 II IV IV IV IV T4 IIIA
>5 and ≤10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
>10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
Duodenum Colorectal
≤2 cm ≤5 I 0 I I T1 I I 0 I I T1 I
>5 and ≤10 III IV II III T1 IIIA III IV II III T1 IIIA
>10 IV I III IV T1 IIIA IV IV III IV T1 IIIA
>2 and
≤5 cm
≤5 II II I II T2 I II II I II T2 I
>5 and ≤10 III IV II III T2 IIIB III IV II III T2 IIIB
>10 IV IV III IV T2 IIIB IV IV III IV T2 IIIB
>5 and
≤10 cm
≤5 III IV II IV T3 II III IV II IV T3 II
>5 and ≤10 IV IV III IV T3 IIIB IV IV III IV T3 IIIB
>10 IV IV IV IV T3 IIIB IV IV IV IV T3 IIIB
>10 cm ≤5 IV IV IV IV T4 IIIA IV IV IV IV T4 IIIA
>5 and ≤10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
>10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
EGIST Esophagus
≤2 cm ≤5 I 0 I I T1 I I 0 I I T1 I
>5 and ≤10 III IV II III T1 IIIA III IV II III T1 IIIA
>10 IV IV III IV T1 IIIA IV IV III IV T1 IIIA
>2 and
≤5 cm
≤5 II II I II T2 I II II I II T2 I
>5 and ≤10 III IV II III T2 IIIB III IV II III T2 IIIB
>10 IV IV III IV T2 IIIB IV IV III IV T2 IIIB
>5 and
≤10 cm
≤5 III III II IV T3 II III III II IV T3 II
>5 and ≤10 IV IV III IV T3 IIIB IV IV III IV T3 IIIB
>10 IV IV IV IV T3 IIIB IV IV IV IV T3 IIIB
>10 cm ≤5 IV IV IV IV T4 IIIA IV IV IV IV T4 IIIA
>5 and ≤10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
>10 IV IV IV IV T4 IIIB IV IV IV IV T4 IIIB
0, None; I, Very Low; II, Low; III, Intermediate; IV, High.
values. The proposed classification byGoh et al. (2008) was finally
not considered, because in our setting (mainly comparing high
and non-high) the results are quite similar to the classification
according to Huang et al. (2007).
For survival analyses the following end-points were used:
GIST-dependent death (disease-specific survival [DSS]),
occurrence of recurrence or metastasis (disease-free survival
[DFS]), as well as death in general (overall-survival [OS]).
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The high-risk group was compared to pooled data of the non-
high-risk-groups. Moreover, survival analyses were performed
between the non-high-risk-groups. To exclude an effect of
TKIs (Imatinib or others), analyses were performed censoring
all end-points and follow-up data after the beginning of TKI
treatment (TKI-adjusted survival).
For the statistical analysis of DSS, DFS and OS, Kaplan-Meier-
curves were compared using the log-rank test after Mantel-Cox.
Additionally, Cox-regression analyses were applied reporting
Hazard Ratios (HR) with corresponding 95% confidence
intervals (CI). Data management was performed using a
professionally developed graphical user interface based on a XML
database. All statistical data was calculated using SPSS V19.0
(IBM Corp., New York, USA). The level of significance was set
to α= 0.05.
The study was approved by the independent Ethics
Committee of the University of Ulm (Study-No: 90 & 91/2006).
All patients gave written informed consent in accordance with
the Declaration of Helsinki.
RESULTS
General Data
The Ulmer GIST Registry comprises a total of 1106 patients with
GIST acquired by multicentric cooperation. Finally, n = 558
patients matched the study criteria.
The male to female ratio was nearly balanced (male n =
268, female n = 290). Mean age at diagnosis was 65.8 years
(SD ± 12.5) whilst the median age was 67.6 years (range: 14.7–
94.8 years). Approximately one quarter of all patients (26.1%)
were younger than 60 years, and 11.3% younger than fifty
years. Patients younger than 40 years represented 3.7% of the
cohort. The predominant proportion of study patients showed
a primary location of GIST in the stomach (69.7%, n = 389).
169 patients (30.3%) revealed a location in the small intestine.
By inclusion criteria only patients with R0-resection have been
considered for analysis. TKIs were used in 10.4% (n = 58) of all
cases.
TKI-adjusted follow-up of more than 3 months was available
for 462 patients (82.8%). Mean and median follow-up time was
4.8 years (SD ± 3.8 years) and 4.2 years (range: 0.1–22.6 years),
respectively. Disease progression (recurrence or metastasis) was
found in 8.2% (n = 46) of all patients. Intraoperative tumor
rupture was not reported. Table 2 summarizes clinical data
as well as the distribution of patients regarding the risk-
classification tools.
General Survival Analysis
GIST-dependent death was reported in 28 cases of whom half
of them received TKI-therapy. Non-GIST related deaths were
more common (n = 89), of which 14.5% had to be censored
due to TKI-intake. In general, 1-, 3-, and 5-years DSS and
OS rates were 98.9, 97.9, and 96.8%, 94.2, 87.2, and 81.9%,
respectively. Metastasis or tumor recurrence occurred in 46
cases of which 10 had to be censored. Finally, the 1-, 3-,
and 5-years DFS rates were 97.3, 94.8 and 93.2%, respectively
(Table 3)
TABLE 2 | Demographic and clinicopathological data of 558 GIST patients
of the Ulmer GIST registry.
Percentage/n Sum
Cases
EPIDEMIOLOGY
Gender (male/female) 48.0/52.0 268/290 558
Mean age at diagnosis (yr
± SD)
65.8 (12.5) 547
Median age at diagnosis
(yr, range)
67.6 (14.7; 94.8) 547
Mean follow-up time (yr
± SD)§
5.2 (3.7)/4.8 (3.8) 529
Median follow-up time (yr,
range)§
4.8 (0.1; 22.6)/4.2 (0.1; 22.6) 529
PATHOLOGY
Localisation (gaster/small
intestine)
69.7/30.3 389/169 558
Mean tumor size (cm ±
SD)
4.8 (4.1) 558
Median tumor size (cm,
range)
3.8 (0.3; 32.0) 558
Histotype
(spindle/epithelioid&mixed)
90.6/9.4 423/44 467
IHC KIT/CD117 (pos/neg) 97.5/2.5 507/13 520
IHC CD34 (pos/neg) 87.9/12.1 350/48 398
IHC Actin (pos/neg) 33.8/66.2 103/202 305
IHC Desmin (pos/neg) 13.4/86.6 39/253 292
IHC S100 (pos/neg) 14.2/85.8 43/260 303
RISK CLASSIFICATION (STANDARDIZED)
Fletcher et al.*1 10.9/22.4/41.2/25.4 61/125/230/142 558
Huang et al.*2 10.6/2.5/21.3/65.6 59/14/119/366 558
Miettinen et al.*3 6.1/11.3/27.8/54.8 34/63/155/306 558
Joensuu*1 17.4/15.9/41.2/25.4 97/89/230/142 558
TNM Stage*4 6.1/11.3/82.6 34/63/461 558
§, TKI-adjusted; SD, standard deviation; yr, years; TKI, tyrosine kinase inhibitor; IHC,
immunohistochemistry; *1, (high, intermediate, low, very low); *2, (level IV, level III, level
II, level I); *3, (high, intermediate, low, very low/none); *4 (Stage III, Stage II, Stage I).
Survival Analysis of Different
Classifications
Results of survival analysis comparing the following groups
(high- vs. non-high risk, intermediate vs. high risk as well as
vs. low/very low) are given in Table 3, indicating significant
inter-group differences (p < 0.001 regarding DSS as well as
DFS, log-rank-tests) except for the classification according to
Joensuu. Lowest survival rates for the high-risk group were
obtained by the classifications according to Miettinen and
Lasota (2006) and the corresponding TNM-classification (Sobin
et al., 2010). 1-, 3-, and 5-years DSS and DFS rates were 86.3,
80.9, and 80.9%, as well as 77.7, 61.7, and 56.1%, respectively.
Corresponding Kaplan-Meier-Plots are given in Figures 1, 2.
Terminal events in non-high risk groups regarding recurrence
of disease or metastasis were less common and appeared
predominantly in patients allocated to the intermediate risk
group. 5-year DFS rates of the intermediate risk groups ranged
between 70.0 and 95.6%. By contrast, 5-years DFS rates in
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TABLE 3 | TKI-adjusted survival rates and Kaplan-Meier log-rank-tests for GIST patients for 1, 3, 5, and 10 years considering different risk classification
systems and standardized mitotic counting.
Classification DSS OAS DFS
Fletcher et al. High 92.5/89.6/89.6/83.2 90.5/84.5/77.2/57.3 85.4/71.4/65.3/60.7
Intermediate 100.0/97.7/94.9/94.9 100.0/96.6/88.1/75.1 98.0/94.7/93.5/84.4
Very Low/Low 99.4/99.0/99.0/98.5 92.8/84.6/80.5/70.8 98.7/97.9/96.9/96.0
NonHigh 99.5/98.7/97.5/97.5 94.5/87.4/82.3/71.6 98.5/97.1/96.1/92.7
Miettinen et al. High 86.3/80.9/80.9/60.7 86.9/75.9/69.0/25.9 77.7/61.7/56.1/56.1
Intermediate 100.0/95.0/89.2/89.2 97.9/93.0/87.3/75.2 95.6/88.3/82.9/79.7
Very Low/Low 99.5/99.2/98.8/98.8 94.1/87.1/81.9/71.5 98.7/97.5/96.7/92.9
NonHigh 99.5/98.7/97.6/97.6 94.6/87.7/82.5/71.8 98.4/96.5/95.2/91.5
Huang et al. Level IV 92.5/89.6/89.6/83.2 90.5/84.5/77.2/57.3 85.4/71.4/65.3/60.6
Level III 100.0/100.0/97.5/n.a. 100.0/100.0/87.5/n.a. 90.0/80.0/70.0/n.a.
Level I/II 99.5/98.6/ 97.8/97.8 94.4/87.1/82.2/ 71.3 98.8/97.6/96.8/93.3
Level I-III 99.5/98.7/97.5/97.5 94.5/87.4/82.3/71.6 98.5/97.1/96.1/92.7
Joensuu High 95.6/90.6/86.6/83.7 94.3/87.7/80.0/64.2 89.9/80.0/74.6/72.1
Intermediate 100.0/100.0/100.0/100.0 100.0/98.4/89.7/76.5 98.6/95.6/95.6/82.8
Very Low/Low 99.4/99.0/98.5/98.5 92.8/84.6/80.5/70.8 98.7/97.9/96.9/96.0
NonHigh 99.5/99.2/98.8/98.8 94.1/87.1/82.2/71.8 98.7/97.5/96.7/92.9
TNM Stage III 86.3/80.9/80.9/60.7 86.9/75.9/69.0/25.9 77.7/61.7/56.1/56.1
Stage II 100.0/95.0/89.2/89.2 97.9/93.0/87.3/75.2 95.6/88.3/82.9/79.7
Stage I 99.5/99.2/98.8/98.8 94.1/87.1/81.9/71.5 98.7/97.5/96.7/92.9
Stage I/II 99.5/98.7/97.6/97.6 94.6/87.7/82.5/71.8 98.4/96.5/95.2/91.5
Overall 98.9/97.9/96.8/96.2 94.2/87.2/81.9/70.4 97.3/94.8/93.2/89.7
Classification p (log-rank-test) p (log-rank-test) p (log-rank-test)
Fletcher et al. (High vs. Non-High) p < 0.001 p = 0.480 p < 0.001
Miettinen et al. (High vs. Non-High) p < 0.001 p = 0.025 p < 0.001
Huang et al. (Level IV vs. I-III) p < 0.001 p = 0.475 p < 0.001
Joensuu (High vs. Non-High) p < 0.001 p = 0.850 p < 0.001
TNM (Stage III vs. Stage I/II) p < 0.001 p = 0.025 p < 0.001
DSS, disease-specific survival; OAS, overall survival; DFS, disease-free survival.
Results with significant p-values are marked as bold.
the combined very low/low-risk groups ranged between 96.7
and 96.9%.
Not only the classification of patients with high-risk of
progression is essential for novel treatment options, but also of
patients with lower risk. Hazard Ratios may be more reliable
to assess the clinical impact of classification systems than
sensitivity and specificity. For prediction of tumor-dependent
death, recurrence of disease and/or metastasis, the classification
according to Miettinen and Lasota (2006) and consistently the
TNM classification (Sobin et al., 2010) revealed highest reliability.
For example, 5-year Hazard ratios for DSS and DFS were
HR= 11.04 [3.317; 36.742] (p < 0.001) and HR= 11.662 [5.224;
26.031] (p < 0.001), respectively. However, due to overlapping
confidence intervals, none of the considered classificationmodels
resulted in superior rating. These results are presented in
Table 4 and are graphically given as Forest-Plots in Figure 3.
Finally, regarding overall survival no significant differences were
found between the highest and the lower risk groups except
for the Miettinen and Lasota (2006) classification (equivalent
to TNM system, Sobin et al., 2010; p = 0.025, log-rank-test,
Table 3).
DISCUSSION
Since the discovery of activating kinase mutations as key targets
for cancer therapy and the definition of GIST as a well-defined
clinicopathological and molecular entity, so far more than eight
risk classification systems have been established. However, most
of them have not been re-evaluated in larger independent studies.
While there is no doubt about the relevance of potent treatment
strategies in case of metastatic GIST, there is currently minor
consensus which treatment option may be best for the subgroup
of non-metastatic and R0-resected GIST. Therefore, the aim of
the present study was to elucidate comparatively the five most
relevant risk GIST assessment models related to standardized
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FIGURE 1 | Kaplan-Meier Plots of disease-free-survival of the high risk group (gray) and the non-high risk group (black) regarding different
classification systems (A, GIST classification acc.to Fletcher et al.; B, acc. to Miettinen et al./TNM; C, acc. to Huang et al.; D, acc. to Joensuu).
clinical endpoints in our independent previously characterized
GIST cohort.
With regard to the clinical and demographic parameters, our
study cohort was not fully comparable to previously published
large series (Miettinen et al., 2005, 2006; Woodall et al., 2009),
because high-risk GIST were often metastasized at time of
diagnosis, consecutively resulting in exclusion of these cases
for our analysis. Thus, an underrepresentation of cases with
metastasis during follow-up may be the consequence indicated
by the high DFS rate of our cohort within the follow-up
interval of 10 years (89.7%, Table 3). Five years DFS rates ranged
from 74.6 to 56.1% for the high-risk group. These results are
comparable to recent findings by Bischof et al., who reported
1−, 3−, and 5-year DFS rates of 95, 83, and 74% (Bischof
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FIGURE 2 | Kaplan-Meier Plots of disease-free-survival for patients of the intermediate risk group (gray) and the low/very low risk group (black)
regarding different classification systems (A, GIST classification acc.to Fletcher et al.; B, acc. to Miettinen et al./TNM; C, acc. to Huang et al.; D, acc. to
Joensuu).
et al., 2015). Furthermore, Kim et al. found a 5-year DFS
rate of 74.9% in high-risk patients with gastric GIST (Kim
et al., 2015). However, in their study, 2.8% had metastasis
prior to operative procedures, 3.7% of all tumors were not R0-
resected and at least 10.2% of all patients received a TKI, which
might restrict comparability. A comparison to largest unbiased
studies by Miettinen et al. (2005, 2006) is limited due to the
lack of definite follow-up times and survival rates. However,
5-years DFS rates seem to be comparable to the reference
study (Miettinen and Lasota, 2006) with given relapse rates for
gastric GIST of 55–86% in high-risk patients (61.9% in our
study) and 12–16% for the intermediate-risk group (20.2% our
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TABLE 4 | Hazard ratios (HR) for disease-specific survival (A), overall-survival (B) and disease-free survival (C) considering different risk classifications
systems and standardized mitotic counting.
HR 1y HR 3y HR 5y HR 10y Overall
A Fletcher et al. (High vs. Non-High) 14.89 [2.48; 89.21] 8.55 [2.29; 31.89] 5.43 [1.63; 18.06] 6.72 [2.19; 20.57] 5.66 [1.88; 16.99]
Miettinen et al. (High vs. Non-High) 29.16 [4.86; 174.74] 17.15 [4.59; 64.05] 11.04 [3.32; 36.74] 14.3 [4.66; 43.9] 14.3 [4.66; 43.9]
Huang et al. (Level IV vs. Level I-III) 14.96 [2.49; 89.59] 8.57 [2.29; 31.96] 5.44 [1.63; 18.09] 6.73 [2.2; 20.61] 5.67 [1.89; 17.02]
Joensuu (High vs. Non-High) 8.04 [1.34; 48.14] 11.04 [2.76; 44.19] 11.03 [3.32; 36.65] 12.11 [3.72; 39.38] 9.45 [3.16; 28.27]
TNM-classification (Stage III vs. Stage I/II) 29.16 [4.86; 174.74] 17.15 [4.59; 64.05] 11.04 [3.32; 36.74] 14.3 [4.66; 43.9] 14.3 [4.66; 43.9]
B Fletcher et al. (High vs. Non-High) 1.55 [0.54; 4.49] 1.21 [0.52; 2.83] 1.27 [0.61; 2.65] 1.38 [0.73; 2.59] 1.25 [0.66; 2.34]
Miettinen et al. (High vs. Non-High) 2.13 [0.64; 7.08] 1.96 [0.78; 4.92] 1.87 [0.81; 4.32] 2.24 [1.08; 4.63] 2.24 [1.08; 4.63]
Huang et al. (Level IV vs. Level I-III) 1.57 [0.54; 4.52] 1.22 [0.52; 2.84] 1.27 [0.61; 2.66] 1.38 [0.73; 2.6] 1.25 [0.67; 2.35]
Joensuu (High vs. Non-High) 0.86 [0.32; 2.5] 0.89 [0.42; 1.88] 1.05 [0.56; 1.96] 1.13 [0.67; 1.91] 1.05 [0.62; 1.77]
TNM-classification (Stage III vs. Stage I/II) 2.13 [0.64; 7.08] 1.96 [0.76; 4.92] 1.87 [0.81; 4.32] 2.24 [1.08; 4.63] 2.24 [1.08; 4.63]
C Fletcher et al. (High vs. Non-High) 10.16 [3.27; 31.58] 11.06 [4.79; 25.55] 10.45 [4.9; 22.26] 8.72 [4.33; 17.55] 8.16 [4.08; 16.3]
Miettinen et al. (High vs. Non-High) 14.31 [4.52; 45.25] 12.96 [5.42; 31.01] 11.66 [5.22; 26.03] 10.02 [4.61; 21.81] 10.02 [4.61; 21.81]
Huang et al. (Level IV vs. Level I-III) 10.22 [3.29; 31.74] 11.09 [4.8; 25.62] 10.47 [4.91; 22.31] 8.73 [4.34; 17.58] 8.17 [4.09; 16.33]
Joensuu (High vs. Non-High) 7.83 [2.45; 24.7] 8.45 [3.61; 19.78] 8.57 [3.97; 18.48] 6.49 [3.23; 13.01] 6.02 [4.04; 11.94]
TNM-classification (Stage III vs. Stage I/II) 14.31 [4.52; 45.25] 12.96 [5.42; 31.01] 11.66 [5.22; 26.03] 10.02 [4.61; 21.81] 10.02 [4.61; 21.81]
Results with significant p-values are marked as bold.
FIGURE 3 | Forest-Plots of Hazard-Ratios of different classification systems (high vs. non-high) regarding disease-specific- (DSS), disease-free-
(DFS), and overall-survival (OAS) (y-axis logarithmic).
study). Considering GIST of the small intestine (except of the
duodenum), Miettinen et al. found relapse rates of 52–90%
(33.7% our study) for the high-risk group and about 24% in the
intermediate-risk group (15.8% our study; Miettinen and Lasota,
2006).
Tumor-dependent death and recurrence of disease or
metastasis were predicted best by the classification of Miettinen
and Lasota (2006). However, as consequence of overlapping
confidence intervals, no classification was superior to the others.
(Table 4, Figures 1, 3).
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Regarding lower risk-groups, survival rates for DSS and DFS
with follow-up to 5 years ranged from 97.5 to 98.8% and from
95.2 to 96.7%, respectively (Table 3). As expected patients with
intermediate risk showed a significant worse outcome compared
to the DFS rates of above 95% for the combined groups with
very low and low risk (Figure 2). Therefore, based on the data
presented it appears to be feasible and justified to combine very
low and low risk patients.
Finally, most interesting are the data regarding OS. Within
a follow-up of 5 years, there was no significant difference
between the high-risk- and the non-high-risk group, except
for classification according to Miettinen et al. (Table 3). This
indicates a prognostic relevance of GIST independent factors—
at least for patients with initially non-metastatic GIST. In our
study, non-GIST-related deaths were more common (n = 89),
which corresponds to 76.1% of all lethal events. Thus, in the
light of a mean age at diagnosis of 65.8 years (SD ± 12.5),
secondary neoplasia (Giuliani and Bonetti, 2015; Murphy et al.,
2015; Kramer et al., 2015b) or other age-related factors, like
cardiovascular diseases may contribute substantially to OS.
Therefore, further studies with representative follow-up times are
required.
Limitation of the presented data might be that the area-
standardized mitotic rates were gained by interpolation. Because
mitotic counting is recommended to be initiated in areas
with the highest proliferative activity, the used method could
underestimate the mitotic rate at least in specimens with distinct
inhomogeneous distribution of mitoses. However, only 34 cases
(5.8%) of the whole cohort showed a mitotic rate ranging from
5 to 20 per 50 HPFs and a size below 10 cm, where calculation
might have had an influence on the final risk allocation anyway.
SYNOPSIS OF DATA AND CONCLUSION
Our data demonstrate that none of the five GIST risk systems
analyzed in our study was superior to predict outcome of patients
with initial non-metastatic and completely resected GIST. Thus,
all these risk classification systems appear to be valid and feasible
for clinical application. We confirmed in our study that indeed
high-risk patients have had highest risk to develop recurrence
of disease or metastasis resulting in a higher rate of tumor
dependent death. Nevertheless, also patients of the intermediate-
risk groups showed partly significant relapse rates within 5-year
follow-up. Subdivision of GIST patients with very low- and low-
risk appears to be negligible. Finally, it is noteworthy that a small
subset of patients with low-risk GISTs developed recurrence of
disease or metastasis within an interval of 10 years. The most
interesting fact however, seems to be the absence of differences
regarding OS between the different risk groups in the majority of
the investigated classification systems.
In summary the analysis of classification systems supports the
fact that tumors subsumed under the rubric GISTs represent a
heterogeneous group of neoplasms that substantially differ in
disease pathogenesis with consequences for tumor progression
and clinical outcome. Heterogeneity in GISTs might not only
be influenced by molecular, but also non-genetic factors such as
age, gender, tumor site, and syndromic occurrence. An important
question arises whether a GIST classification system in the
future would be able to consider all important predictive factors?
Of course, standardization of such a classification system with
international consensus is obligate incorporating also a precise
description of valid methods for mitotic counting (i.e., defining
the best cut-off area and cut-off mitotic index based on validated
prognostic studies). At present, current treatment strategies
remain to be used, as long as there are no more obvious data on
potential, additional risk factors regarding prognostic impact.
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